Clinical trials: Tissue Plasminogen Activator
Stroke
Alteplase in Elderly Acute Ischemic Stroke (AIS) Patients During Hospitalization
The objective of the study is to find out the in-hospital clinical outcomes among Chinese Acute Ischaemic Stroke (AIS) patients, who were treated with intravenous (IV) Recombinant Tissue Plasminogen Activator (rt-PA) within 4.5…
- Trial name
- NCT05395351
- Testing
- rt-PA
- Where
- China
- Volunteers
- 113,035 people
- Sponsor
- Boehringer Ingelheim
Myocardial Infarction
Trial to Compare the Efficacy and Safety of a Single Bolus of TNK-tPA (Tenecteplase, Metalyse®) With Accelerated Infusion of Rt-PA (Alteplase, Actilyse®) in Asian Patients With Acute Myocardial Infarction
The objective of this trial was to compare the efficacy and safety of a single bolus of TNK-tPA (tenecteplase, Metalyse®) compared with rt-PA (alteplase, Actilyse®) in Asian patients.
- Trial name
- NCT00148460
- Testing
- TNK-tPA, rt-PA
- Where
- 18 sites in China, Hong Kong and 1 more
- Volunteers
- 270 people
- Sponsor
- Boehringer Ingelheim
Myocardial Infarction
Full Dose Tenecteplase (TNK-tPA) Together With Heparin Sodium, Full Dose Tenecteplase With Enoxaparin, Half Dose Tenecteplase Together With Abciximab and Heparin Sodium in Patients With Acute Myocardial Infarction (AMI)
The objective of ASSENT 3 was to evaluate the safety and efficacy of full dose tenecteplase with heparin sodium (group A), full dose tenecteplase combined with enoxaparin (group B) and half dose tenecteplase combined with…
- Trial name
- ASSENT 3 (NCT02181985)
- Testing
- Full dose TNK-tPA, Half dose TNK-tPA, Heparin
- Volunteers
- 5,989 people
- Sponsor
- Boehringer Ingelheim
Ischemic Stroke
Efficacy and Safety of SP-8203 in Patients With Ischemic Stroke Requiring rtPA
This clinical trial is designed to evaluate the efficacy and safety of the combination therapy of SP-8203 (Otaplimastat) and recombinant tissue Plasminogen Activator (rtPA) standard of care.
- Trial name
- SP-8203-2002 (NCT04479449)
- Testing
- SP-8203
- Where
- South Korea
- Volunteers
- 178 people
- Sponsor
- Shin Poong Pharmaceutical Co. Ltd.
Hypertension, Hypercholesterolemia
Efficacy and Safety of Valsartan and the Combination of Valsartan and Simvastatin
This study will assess and compare the efficacy and safety of valsartan and the combination of valsartan and simvastatin in patients with high blood pressure and high cholesterol.
- Conditions
- Hypertension, Hypercholesterolemia, Dyslipidemia
- Trial name
- NCT00385931
- Testing
- Valsartan and simvastatin
- Where
- United States
- Volunteers
- 412 people
- Sponsor
- Novartis
Acute Ischemic Stroke
Aureva Transcranial Ultrasound Device With tPA in Patients With Acute Ischemic Stroke
This is a randomized, placebo controlled, double-blind phase 3 clinical study to evaluate the efficacy and safety of transcranial ultrasound (TUS) using the Sonolysis Headframe as an adjunctive therapy to intravenous (IV) tissue…
- Trial name
- TRUST (NCT03519737)
- Testing
- tPA in combination with the Sonolysis Headframe (TUS)
- Where
- 2 sites in United States
- Volunteers
- 596 people
- Sponsor
- Cerevast Medical, Inc.
Massive Pulmonary Embolism
Massive Pulmonary Embolism: Trial of Non-immunogenic Recombinant Staphylokinase VS Alteplase FORPE
Objective: to evaluate the efficacy and safety of the Recombinant Non-immunogenic Staphylokinase with its single bolus administration in comparison with the bolus-infusion administration of the Alteplase in patients with massive…
- Trial name
- NCT04688320
- Testing
- Recombinant nonimmunogenic staphylokinase, Alteplase
- Where
- 23 sites in Russia
- Volunteers
- 310 people
- Sponsor
- Supergene, LLC
Thrombosis
Study Investigation Pharmacokinetics and Pharmacodynamics of CS1
SAD study: Eighteen subjects will be included in the SAD study (single dose) in 3 parallel arms, each with 6 subjects. The 3 arms will receive a single dose of one of the CS1 formulations I, II or III.
- Trial name
- NCT03903302
- Testing
- CS1-Sodium Valproate
- Where
- Sweden
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Cereno Scientific AB
Ischemic Stroke
A Safety Evaluation of the Use of Magnetic-guided Iron Particles
This study is a prospective trial wherein each included subject will receive the experimental magnetically enhanced diffusion therapy.
- Trial name
- NCT01519076
- Testing
- Pulse Therapeutics (PTI) Magnetically-Enhanced Diffusion (MED)
- Where
- 2 sites in Australia
- Volunteers
- 7 people
- Sponsor
- Pulse Therapeutics
Myocardial Infarction
A Study of Pre-hospital Treatment of Acute Myocardial Infarction Based on Diagnosis by Interpretation of Remotely Acquired ECG and Thrombolysis With Accelerated Alteplase ( Actilyse®)
The general aim of this study was to assess the feasibility of treating acute myocardial infarction (AMI) by physician-directed pre-hospital thrombosis, using accelerated alteplase (Actilyse®) and a diagnostic technique involving…
- Trial name
- PHARAOH (NCT02235389)
- Testing
- Alteplase (Actilyse), Standard therapy
- Volunteers
- 59 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Embolism
tPA by Endovascular Administration for the Treatment of Submassive PE Using CDT for the Reduction of Thrombus Burden
To demonstrate the efficacy and safety of the Bashir™ Endovascular Catheter for the administration of pharmaco-mechanical catheter directed therapy using low dose r-tPA for the treatment of acute submassive pulmonary embolism.
- Trial name
- RESCUE (NCT04248868)
- Testing
- The Bashir™ Endovascular Catheter, r-tPA
- Where
- 19 sites in United States
- Volunteers
- 109 people
- Sponsor
- Thrombolex, Inc.
Acute Ischemic Stroke
Transcranial Ultrasound in Clinical SONothrombolysis
This is a randomized, placebo controlled, parallel group dose escalation trial to evaluate the safety, tolerability, and activity of four sequential dose tiers of MRX-801 and ultrasound as an adjunctive therapy to tissue…
- Trial name
- TUCSON (NCT00504842)
- Testing
- MRX-801
- Where
- 14 sites in United States, France
- Volunteers
- 72 people
- Sponsor
- ImaRx Therapeutics
Healthy
A Study in Healthy Men to Compare 2 Different Formulations of Alteplase
To establish the bioequivalence of alteplase derived from two different manufacturing processes.
- Trial name
- NCT04419493
- Testing
- Alteplase (from modified manufacturing process), Alteplase (from current manufacturing process), Heparin-Natrium-5000-ratiopharm (unfractionated heparin)
- Where
- Germany
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Myocardial Infarction
A Study to Investigate the Procoagulant Effect of Tenecteplase (TNK-tPA), Alteplase (Rt-PA) and Streptokinase (SK) Administered to Patients With Acute Myocardial Infarction (AMI)
Primary objective: to evaluate the procoagulant effect of TNK-tPA compared to rt-PA and streptokinase, administered to patients with AMI, by measuring the concentration of TAT at 2 hours after the start of treatment versus…
- Trial name
- NCT02182011
- Testing
- Tenecteplase, Alteplase, Streptokinase
- Volunteers
- 49 people
- Sponsor
- Boehringer Ingelheim
Acute Stroke, Ischemic Stroke
Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)
This is a Phase 2/3 study evaluating the safety and efficacy of DM199 (rinvecalinase alfa) in treating participants with moderate stroke severity, who present within 24 hours of Acute Ischemic Stroke (AIS) onset due to small and…
- Conditions
- Acute Stroke, Ischemic Stroke, Stroke
- Trial name
- ReMEDy2 (NCT05065216)
- Testing
- Recombinant human tissue kallikrein
- Where
- 86 sites in United States, Belgium and 8 more
- Volunteers
- 728 people
- Sponsor
- DiaMedica Therapeutics Inc
Acute Ischemic Stroke
A Study to Evaluate the Effects of YM872 on Brain Function and Disability When Administered in Combination With Alteplase (Tissue Plasminogen Activator)
The purpose of this study is to determine if YM872 in combination with t-PA can reduce disability and brain damage from stroke. YM872 or placebo will be given as a continuous intravenous (iv) infusion for 24 hours.
- Trial name
- NCT00044057
- Testing
- YM872 (zonampanel), t-PA (alteplase)
- Where
- 118 sites in United States, Austria and 3 more
- Sponsor
- Astellas Pharma Inc
Cerebral Infarction, Brain Ischemia
Japan Alteplase Clinical Trial (J-ACT): Efficacy and Safety Study of Tissue Plasminogen Activator (Alteplase) for Ischemic Stroke
Based on previous studies comparing Duteplase[a recombinant tissue plasminogen activator (rt-PA) very similar to alteplase] doses, we performed a clinical trial with 0.6mg/kg, which is lower than the internationally approved…
- Trial name
- NCT00147316
- Testing
- Alteplase
- Where
- Japan
- Volunteers
- 103 people
- Sponsor
- Tanabe Pharma Corporation
Stroke
Post-marketing Clinical Study of Alteplase for Acute Ischemic Stroke （Japan Alteplase Clinical Trial Ⅱ：J-ACT Ⅱ）
The purpose of this study is to confirm the efficacy and safety of intravenously administered alteplase in patients with acute ischemic stroke based on the rate of recanalization assessed by magnetic resonance angiography (MRA)…
- Trial name
- NCT00412867
- Testing
- Alteplase
- Where
- Japan
- Volunteers
- 58 people
- Sponsor
- Tanabe Pharma Corporation
Acute Limb Ischemia
Evaluation of MST-188 in Acute Lower Limb Ischemia
The purpose of this study is to evaluate the safety and efficacy of MST-188 in subjects receiving catheter-directed rt-PA for acute lower limb ischemia and to evaluate whether treatment with MST-188 results in more rapid…
- Trial name
- NCT02093468
- Testing
- MST-188, Saline
- Where
- 4 sites in United States
- Volunteers
- 4 people
- Sponsor
- Mast Therapeutics, Inc.
Stroke
Protocol for Post Marketing Surveillance of Actilyse Vial
The objectives of this study are to review the safety and efficacy of Actilyse Vial (hereafter referred to as "Actilyse") in post-marketing use for treatment of acute ischemic stroke, through investigating followings; 1.
- Trial name
- NCT02229799
- Testing
- Actilyse
- Volunteers
- 265 people
- Sponsor
- Boehringer Ingelheim